Abstract
Aims: This study, conducted in a 'field-practice' scenario, investigates the effectiveness and safety of everolimus in the second-line treatment of metastatic renal cell carcinoma (mRCC) patients. Patients & methods: mRCC patients, who started everolimus 10 mg/day after failure of first-line VEGF receptor-targeted tyrosine kinase inhibitor, were included in this study. Study end points were treatment response, progression-free survival and tolerability. Results: In total, 100 patients were assessed; the median duration of everolimus treatment was 7.1 months (95% CI: 5.7-8.5). A total of 19% of patients experienced a partial response and 62% of patients reached a stable disease. Median progression-free survival was 8 months (95% CI: 6.7-9.3). A total of 75% of patients experienced adverse events; no grade 4 adverse events were reported. Conclusion: These findings, obtained in a 'field-practice' scenario, support the use of everolimus for mRCC patients who failed one VEGF receptor-targeted tyrosine kinase inhibitor.
| Original language | English |
|---|---|
| Pages (from-to) | 219-224 |
| Number of pages | 6 |
| Journal | Future Oncology |
| Volume | 11 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jan 1 2015 |
Fingerprint
Keywords
- everolimus
- mRCC
- observational studies
- second-line therapy
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Medicine(all)
Cite this
Everolimus as second-line therapy for metastatic renal cell carcinoma : A 'real-life' study. / Rizzo, Mimma; Facchini, Gaetano; Savastano, Clementina; Lorenzo, Giuseppe Di; Lucia, Luigi De; Maiorino, Luigi; Casale, Beniamino; Grimaldi, Giuseppe; Formato, Roberta; Febbraro, Antonio; Cartenì, Giacomo.
In: Future Oncology, Vol. 11, No. 2, 01.01.2015, p. 219-224.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Everolimus as second-line therapy for metastatic renal cell carcinoma
T2 - A 'real-life' study
AU - Rizzo, Mimma
AU - Facchini, Gaetano
AU - Savastano, Clementina
AU - Lorenzo, Giuseppe Di
AU - Lucia, Luigi De
AU - Maiorino, Luigi
AU - Casale, Beniamino
AU - Grimaldi, Giuseppe
AU - Formato, Roberta
AU - Febbraro, Antonio
AU - Cartenì, Giacomo
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Aims: This study, conducted in a 'field-practice' scenario, investigates the effectiveness and safety of everolimus in the second-line treatment of metastatic renal cell carcinoma (mRCC) patients. Patients & methods: mRCC patients, who started everolimus 10 mg/day after failure of first-line VEGF receptor-targeted tyrosine kinase inhibitor, were included in this study. Study end points were treatment response, progression-free survival and tolerability. Results: In total, 100 patients were assessed; the median duration of everolimus treatment was 7.1 months (95% CI: 5.7-8.5). A total of 19% of patients experienced a partial response and 62% of patients reached a stable disease. Median progression-free survival was 8 months (95% CI: 6.7-9.3). A total of 75% of patients experienced adverse events; no grade 4 adverse events were reported. Conclusion: These findings, obtained in a 'field-practice' scenario, support the use of everolimus for mRCC patients who failed one VEGF receptor-targeted tyrosine kinase inhibitor.
AB - Aims: This study, conducted in a 'field-practice' scenario, investigates the effectiveness and safety of everolimus in the second-line treatment of metastatic renal cell carcinoma (mRCC) patients. Patients & methods: mRCC patients, who started everolimus 10 mg/day after failure of first-line VEGF receptor-targeted tyrosine kinase inhibitor, were included in this study. Study end points were treatment response, progression-free survival and tolerability. Results: In total, 100 patients were assessed; the median duration of everolimus treatment was 7.1 months (95% CI: 5.7-8.5). A total of 19% of patients experienced a partial response and 62% of patients reached a stable disease. Median progression-free survival was 8 months (95% CI: 6.7-9.3). A total of 75% of patients experienced adverse events; no grade 4 adverse events were reported. Conclusion: These findings, obtained in a 'field-practice' scenario, support the use of everolimus for mRCC patients who failed one VEGF receptor-targeted tyrosine kinase inhibitor.
KW - everolimus
KW - mRCC
KW - observational studies
KW - second-line therapy
UR - http://www.scopus.com/inward/record.url?scp=84921373590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921373590&partnerID=8YFLogxK
U2 - 10.2217/fon.14.170
DO - 10.2217/fon.14.170
M3 - Article
C2 - 25078333
AN - SCOPUS:84921373590
VL - 11
SP - 219
EP - 224
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 2
ER -